Spyre Therapeutics (SYRE.O) gains after Merck drug validates TL1A pathway
Spyre Therapeutics shares rose 6.08% to $89.87 after Merck & Co's experimental drug tulisokibart showed success in a skin disease trial, validating the TL1A drug class and supporting Spyre's candidates targeting the same pathway.